How can we help?
Avoid blind spots in your market. Get the insights you need to accelerate innovation.
Austin, TX November 06, 2015 – This past Wednesday, Qiagen announced the launch of its GeneReader NGS system at the Association for Molecular Pathology (AMP) meeting in Austin, TX.
The GeneReader NGS dovetails in other instruments and solutions that Qiagen has been commercializing for quite some time: the QiaCube (automated DNA extraction), the QiaCube NGS (automated library construction), and Qiagen Clinical Insight (clinical decision support). The launch of this platform is in line with the expectation outlined in our NGS report published earlier this week. Just like the S5 / S5 XL before it, the GeneReader platform highlights how NGS instrument manufacturers are increasingly developing clinical solutions differentiated on dimensions beyond the cost / throughput axis. Ease of workflow / “sample-to-insight” solutions can be as important as throughput to clinical lab directors, especially for oncology applications that use small gene panels.
The long awaited system launches along with the Actionable Insights Tumor Panel, a 12-gene cancer panel targeting genes clinically actionable genes selected based on guidelines and favorable reimbursement. The current panel focuses on tumor types of high prevalence and high societal impact: breast cancer, ovarian cancer, colorectal cancer, lung cancer and melanoma. The panel builds on the previously commercialized GeneRead DNAseq V2 panel; it can detect up to 1,250 mutations. While pricing has not been announced, it is expected to be in the $300-400 range.
We talked with Yi Kong, Director of Marketing at the AMP Qiagen booth. She confirmed that the target customers are medium- to low-throughput labs new to sequencing. “We have a small panel, and offer a full sample-to-insight solution” Kong said. “We believe actionability of the results and ease-of-use will enable labs to adopt NGS in-house.”
The company offers 3 pricing models to accommodate labs with various volumes (and based on their preference in different countries):
Over the last couple of days, we collected feedback from the community from AMP, talking with Qiagen representatives, as well as potential customers showing interest in the platform at the Qiagen AMP booth.
Qiagen highlighted the following instrument specifications:
Disclaimer: Some of the companies listed in this entry may be DeciBio clients or customers